Unicycive Therapeutics publishes corporate presentation on kidney disease drug pipeline

• Unicycive highlighted oxylanthanum carbonate (OLC) as its lead program for hyperphosphatemia in CKD patients on dialysis, with approval expected near-term pending NDA resubmission.
• CRL tied to third-party manufacturing deficiencies; FDA inspection of the contract manufacturer expected in the near term; label and packaging discussions ongoing.
• Positioned OLC for a >USD 1 billion US hyperphosphatemia market; cited >550,000 US dialysis patients, with about 80% using phosphate binders.
• Pivotal study: no treatment-related serious adverse events; discontinuations due to adverse events were 6% in 86 patients.
• Cash runway projected into 2027 to support a potential OLC approval and launch; UNI-494 remains in development for acute kidney injury.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief on July 31, 2026, and is solely responsible for the information contained therein.